Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01730950 |
Recruitment Status :
Completed
First Posted : November 21, 2012
Results First Posted : March 17, 2020
Last Update Posted : December 29, 2022
|
Sponsor:
Radiation Therapy Oncology Group
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Radiation Therapy Oncology Group
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
Conditions |
Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Tumor |
Interventions |
Biological: bevacizumab Radiation: radiation therapy |
Enrollment | 182 |
Participant Flow
Recruitment Details | |
Pre-assignment Details |
Arm/Group Title | Bevacizumab | Bevacizumab + RT |
---|---|---|
Arm/Group Description | Bevacizumab (IV 10mg/kg) every 2 weeks until disease progression. | Radiation therapy (35Gy in 10 fractions of 3.5 Gy) with bevacizumab (IV 10mg/kg) every 2 weeks until disease progression. |
Period Title: Overall Study | ||
Started | 90 | 92 |
Eligible Population | 84 | 86 |
Adverse Event Population [1] | 76 | 83 |
Response Population [2] | 78 | 77 |
6-month Progression-free Analysis [3] | 79 | 81 |
Delayed Toxicity Population [4] | 0 | 83 |
Completed [5] | 84 | 86 |
Not Completed | 6 | 6 |
Reason Not Completed | ||
Protocol Violation | 6 | 6 |
[1]
Eligible participants who started protocol treatment
[2]
Eligible participants with response evaluations
[3]
Eligible participants with data at 6 months
[4]
Eligible participants on RT arm who started RT and were alive at least 91 days from the start of RT
[5]
Subjects contributing data to results are considered to have completed the study.
|
Baseline Characteristics
Arm/Group Title | Bevacizumab | Bevacizumab + RT | Total | |
---|---|---|---|---|
Arm/Group Description | Bevacizumab (IV 10mg/kg) every 2 weeks until disease progression. | Radiation therapy (35Gy in 10 fractions of 3.5 Gy) with bevacizumab (IV 10mg/kg) every 2 weeks until disease progression. | Total of all reporting groups | |
Overall Number of Baseline Participants | 84 | 86 | 170 | |
Baseline Analysis Population Description |
Eligible participants
|
|||
Age, Continuous
Median (Full Range) Unit of measure: Years |
||||
Number Analyzed | 84 participants | 86 participants | 170 participants | |
57
(25 to 87)
|
60
(28 to 81)
|
59
(25 to 87)
|
||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 84 participants | 86 participants | 170 participants | |
Female |
38 45.2%
|
43 50.0%
|
81 47.6%
|
|
Male |
46 54.8%
|
43 50.0%
|
89 52.4%
|
|
Ethnicity (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 84 participants | 86 participants | 170 participants | |
Hispanic or Latino |
8 9.5%
|
3 3.5%
|
11 6.5%
|
|
Not Hispanic or Latino |
72 85.7%
|
81 94.2%
|
153 90.0%
|
|
Unknown or Not Reported |
4 4.8%
|
2 2.3%
|
6 3.5%
|
|
Race (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 84 participants | 86 participants | 170 participants | |
American Indian or Alaska Native |
4 4.8%
|
0 0.0%
|
4 2.4%
|
|
Asian |
6 7.1%
|
2 2.3%
|
8 4.7%
|
|
Native Hawaiian or Other Pacific Islander |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Black or African American |
3 3.6%
|
2 2.3%
|
5 2.9%
|
|
White |
66 78.6%
|
75 87.2%
|
141 82.9%
|
|
More than one race |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Unknown or Not Reported |
5 6.0%
|
7 8.1%
|
12 7.1%
|
|
Karnofsky Performance Status
[1] Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 84 participants | 86 participants | 170 participants | |
60 |
3 3.6%
|
8 9.3%
|
11 6.5%
|
|
70-80 |
42 50.0%
|
41 47.7%
|
83 48.8%
|
|
90-100 |
39 46.4%
|
37 43.0%
|
76 44.7%
|
|
[1]
Measure Description: 60 = Requires occasional assistance, but is able to care for most personal needs; 70 = Cares for self; unable to carry on normal activity or to do active work; 80 = Normal activity with effort; some signs or symptoms of disease; 90 = Able to carry on normal activity, minor signs or symptoms of disease; 100 = Normal no complaints; no evidence of disease.
|
||||
Neurologic Function
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 84 participants | 86 participants | 170 participants | |
No symptoms |
21 25.0%
|
24 27.9%
|
45 26.5%
|
|
Minor symptoms |
40 47.6%
|
36 41.9%
|
76 44.7%
|
|
Moderate symptoms (fully active) |
17 20.2%
|
15 17.4%
|
32 18.8%
|
|
Moderate symptoms (required assistance) |
6 7.1%
|
9 10.5%
|
15 8.8%
|
|
Severe symptoms |
0 0.0%
|
2 2.3%
|
2 1.2%
|
|
Surgery for Initial Brain Tumor
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 84 participants | 86 participants | 170 participants | |
Biopsy only |
8 9.5%
|
7 8.1%
|
15 8.8%
|
|
Subtotal resection |
20 23.8%
|
25 29.1%
|
45 26.5%
|
|
Gross total resection |
56 66.7%
|
52 60.5%
|
108 63.5%
|
|
Other |
0 0.0%
|
2 2.3%
|
2 1.2%
|
|
Recent Resection
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 84 participants | 86 participants | 170 participants | |
No / biopsy only |
49 58.3%
|
57 66.3%
|
106 62.4%
|
|
Yes |
35 41.7%
|
29 33.7%
|
64 37.6%
|
|
Histologic Tumor Type
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 84 participants | 86 participants | 170 participants | |
Glioblastoma (WHO Grade IV) |
79 94.0%
|
82 95.3%
|
161 94.7%
|
|
Gliosarcoma |
2 2.4%
|
2 2.3%
|
4 2.4%
|
|
Other |
3 3.6%
|
2 2.3%
|
5 2.9%
|
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
the PI's rights to discuss or publish trial results after the trial is completed.
PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.
Results Point of Contact
Name/Title: | Wendy Seiferheld |
Organization: | NRG Oncology |
Phone: | 215-574-3208 |
EMail: | seiferheldw@nrgoncology.org |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Radiation Therapy Oncology Group |
ClinicalTrials.gov Identifier: | NCT01730950 |
Obsolete Identifiers: | NCT02671981 |
Other Study ID Numbers: |
RTOG-1205 NCI-2012-01732 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) U10CA021661 ( U.S. NIH Grant/Contract ) |
First Submitted: | November 15, 2012 |
First Posted: | November 21, 2012 |
Results First Submitted: | February 20, 2020 |
Results First Posted: | March 17, 2020 |
Last Update Posted: | December 29, 2022 |